Nevertheless, the analysis of pretreatment HNSCC patient samples from TCGA [36] and another study [42] confirmed that our finding that FGFR1 is upregulated and demethylated in HNSCC and associated with acquired resistance to cetuximab is also a mechanism involved in intrinsic resistance to the targeted therapy. This evidence concerns the gene FGFR1 and head and neck squamous cell carcinoma.